We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Corcept Therapeutics (CORT) Could Be Positioned for a Surge
Read MoreHide Full Article
Corcept Therapeutics Incorporated (CORT - Free Report) is a pharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on CORT’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Corcept Therapeutics could be a solid choice for investors.
Current Quarter Estimates for CORT
In the past 30 days, two estimates have gone higher for Corcept Therapeutics while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from 9 cents a share 30 days ago, to 15 cents today, a move of 66.7%.
Current Year Estimates for CORT
Meanwhile, Corcept Therapeutics’ current year figures are also looking quite promising, with three estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, increasing from 26 cents per share 30 days ago to 43 cents per share today, an increase of 65.4%.
Corcept Therapeutics Incorporated Price and Consensus
The stock has also started to move higher lately, adding 13.9% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Corcept Therapeutics (CORT) Could Be Positioned for a Surge
Corcept Therapeutics Incorporated (CORT - Free Report) is a pharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on CORT’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Corcept Therapeutics could be a solid choice for investors.
Current Quarter Estimates for CORT
In the past 30 days, two estimates have gone higher for Corcept Therapeutics while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from 9 cents a share 30 days ago, to 15 cents today, a move of 66.7%.
Current Year Estimates for CORT
Meanwhile, Corcept Therapeutics’ current year figures are also looking quite promising, with three estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, increasing from 26 cents per share 30 days ago to 43 cents per share today, an increase of 65.4%.
Corcept Therapeutics Incorporated Price and Consensus
Corcept Therapeutics Incorporated Price and Consensus | Corcept Therapeutics Incorporated Quote
Bottom Line
The stock has also started to move higher lately, adding 13.9% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>